Antibiotic resistance refers to bacteria becoming resistant to the drugs used to treat the infections they cause. Antibiotics are used to treat bacterial infections like pneumonia, urinary tract infections (UTIs), gonorrhea, and others. However, overuse and misuse of antibiotics has contributed to the growing problem of antibiotic resistance. Antibiotic resistance occurs through natural selection, whereby bacteria possessing genes that help them survive treatment outcompete and replace those bacteria killed off by the antibiotics. When bacteria evolve resistance, antibiotics become ineffective at the doses normally used to treat infections in humans.
The Global Antibiotic Resistance Market is estimated to be valued at US$ 8.83 billion in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.
The global antibiotic resistance market is driven by the rising prevalence of infectious diseases coupled with the increasing resistance of microbes to existing antibiotics. Antibiotic-resistant infections are difficult to treat as standard antibiotics become ineffective. This has necessitated the need for development of novel anti-infectives. Antibiotic resistance occurs as a natural evolutionary response in bacteria to fight against strong selection pressure of antibiotics. However, this process has been rapidly accelerated due to overuse and misuse of existing antibiotics.
Key Takeaways
Key players operating in the Global Antibiotic Resistance Market Demand are Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nemisis Biomedical Technologies and NEMESIS BIOSCIENCE LTD.
Key opportunities in the market include increasing clinical trials to develop novel anti-infectives, growing investment in R&D for new drug discovery, partnerships between companies and academic research institutions.
The major companies are focusing on expanding their product offerings and global footprint in regions such as North America, Europe, Asia Pacific and Rest of the world to tap into the lucrative opportunities.
Market Drivers
- Rising prevalence of infectious diseases propelled by the emergence of novel infectious strains and pandemics is a major factor contributing to the growth of antibiotic resistance. According to the WHO, antimicrobial resistance causes around 700,000 deaths each year globally.
- Excessive antibiotic use in livestock farming and aquaculture has contributed significantly to the emergence and spread of resistant bacteria.
Market Restraints
- Developing new antibiotics is a challenging, costly and time-consuming process. The clinical failure rate for new antibiotics is very high.
- Stringent regulatory environment delays the approval and market launch of new anti-infectives. This hinders faster development of effective treatment alternatives.
- Prudent use policies and antibiotic stewardship programs restrict the use and prescribing of newer broad-spectrum antibiotics, limiting growth opportunities.
Segment Analysis
The global antibiotic resistance market is dominated by the hospital acquired infections sub segment due to increase prevalence of drug resistant pathogens causing HAIs every year. These infections are difficult to treat as the pathogens have become resistant to existing last line of antibiotic treatments. According to WHO, Antibiotic resistant bacteria cause over 700,000 deaths every year globally due to HAIs. Most common HAIs include surgical site infections, urinary tract infections, pneumonia etc.
Global Analysis
North America accounts for the largest share in the global antibiotic resistance market led by U.S. due to high prevalence of drug resistant infections and rapidly aging population which is more prone to HAIs. The region is expected to witness significant growth during the forecast period due high awareness regarding antibiotic resistance and research initiatives taken by both public and private organizations in developing new resistant drugs. Asia Pacific is anticipated to grow at the fastest pace in the antibiotic resistance market, majorly driven by China, India and other southeast Asian countries. Factors such as increasing healthcare expenditure, large patient pool suffering from infectious diseases and growing R&D investments will contribute to the regional market growth.
Get more insights on Global Antibiotic Resistance Market
Antibiotic Resistance Market: Information by Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies and others), Disease (Complicated Urinary Tract Infection (cUTI), Blood Stream Infections (BDS), Complicated Intra-Abdominal Infections (cIAI), Clostridium Difficile Infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Community-Acquired Bacterial Pneumonia (CABP), Others), Pathogen (Staphylococcus Aureus , Streptococcus pneumonia, Acinetobacter, Enterococcus Faecium, Hemophilus Influenzae, Pseudomonas Aeruginosa, Clostridium Difficile, K. Pneumoniae, Others), End-User (Hospitals and Clinics, Research Organizations and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027Antibiotic Resistance Market-OverviewThe popularity and effectiveness of antibiotics have risen exponentially since their mainstream introduction.
The pharmaceutical reports are made by Market Research Future, which includes market options for expansion.
A USD 13,146 Million is estimated to be accumulated by the market by 2025 while progressing at a CAGR of 5.8%.The natural occurrence of resistance to antibiotics to their intensive or prolonged use is estimated to create an augmented scope for the antibiotic resistance market growth.
Based on disease, the antibiotic resistance market has been segmented into hospital-acquired bacterial pneumonia/ventilator, complicated urinary tract infections, complicated intra-abdominal infections, bloodstream infections, community-acquired bacterial pneumonia, acute bacterial and skin structure infections, clostridium difficile infections, and others.
On the basis of pathogen, the antibiotic resistance market is segmented into streptococcus pneumoniae, k. pneumoniae, acinetobacter, staphylococcus aureus, enterococcus, pseudomonas aeruginosa, clostridium difficile, hemophilus influenzae, campylobacter, and others.Detailed Regional Analysis The regional examination of the antibiotic resistance market is conducted for regions such as Americas, Asia-Pacific the Middle East, Europe and Africa.
The intensifying growth in the pharmaceutical sector, intensifying approval of antibiotic resistance, mounting prevalence of communicable diseases are the noteworthy factors that would propel the development of the antibiotic resistance market in this region.
Market HighlightsAccording to MRFR analysis, Antibiotic Resistance Market is expected to register a CAGR of 5.8% during the forecast period of 2019 to 2025 and was valued at USD 8,120 Million in 2018.Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi, and parasites change when they are exposed to antimicrobial drugs.
Antibiotic drugs include antibiotics, antifungals, antivirals, antimalarials, and anthelmintic.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/8579The growth of global antibiotic resistance market is driven by various factors such as - Rising antibiotic drug resistance infections, rise in the incidence of chronic and infectious disease, increase in clinical developments of antibiotic resistance, and rise in global initiatives to control drug-resistance Several market players currently dominate the global antibiotic resistance market.
The Americas is expected to be the largest market owing to the rising growth in the pharmaceutical sector.
The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The antibiotic resistance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
Additionally, it has minimal treatment options available with the increasing demand for antibiotic resistance, thus driving the growth of this segment.The global antibiotic resistance market has been bifurcated, based on disease, into complicated urinary tract infections, bloodstream infections, complicated intra-abdominal infections, clostridium difficile infections, acute bacterial and skin structure infections, hospital-acquired bacterial pneumonia/ventilator, community-acquired bacterial pneumonia, and others.
Antibiotic Resistance market report is of immense importance for better understanding of the market which leads to high business growth.
It highlights public demands, competencies and the constant growth of the working industry, vibrant reporting, or high data protection services while analysing market information.
A lot of hard work has been put together and no stone is left unturned while generating this market research report.
This Antibiotic Resistance market report defines a chapter on the global market and allied companies with their profiles, which provides important data pertaining to their insights in terms of finances, product portfolios, investment plans, and marketing and business strategies.Global antibiotic resistance market is growing at a substantial CAGR in the forecast period of 2019-2026.
Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growthAntibiotic Resistance market report delivers an in depth study with present and upcoming opportunities to clarify the future investment in the market.
The market research also provides information about manufacturers, market competition, cost, market effect factors for the forecast period of 2019-2026.
